Development and Characterization of Ranolazine-Loaded Solid Lipid Nanoparticles for Enhanced Angina Therapy

Background: The study focuses on the development and characterization of Ranolazine-loaded Solid Lipid Nanoparticles (RNZ-SLNs) to enhance therapeutic efficacy and safety in angina therapy. Materials and Methods: RNZ-SLNs were synthesized using a heated homogenization process followed by ultrasonication. The formulation was characterized for particle size, zeta potential, % entrapement efficiency, and in vitro drug release profile. Biocompatibility was evaluated using in vitro hemolysis studies. Results and Discussion: The results of the study demonstrated that the formulated Ranolazine-loaded Solid Lipid Nanoparticles (RNZ-SLNs) exhibited favorable physicochemical properties essential for effective drug delivery. The particle size of the RNZ-SLNs was found to be 254.1±2.4 nm, indicating their suitability for nanoparticle-based drug delivery systems. The zeta potential of -15.3±1.8 mV reflected sufficient stability of the formulation, while the % entrapement efficiency of 75.15±3.1% confirmed the effective incorporation of Ranolazine within the lipid matrix. The in vitro drug release profile revealed a significantly enhanced release rate for RNZ-SLNs, achieving 61.807±2.51% over 24 hr, compared to the plain Ranolazine dispersion, which released only 36.807±2.08% within the same period. Furthermore, in vitro hemolysis studies indicated a marked improvement in biocompatibility for RNZ-SLNs, with a hemolytic effect of 9.17%, compared to 19.23% observed for plain Ranolazine. These findings collectively highlight the potential of RNZ-SLNs to improve the therapeutic efficacy and safety profile of Ranolazine for angina therapy. Conclusion: RNZ-SLNs demonstrated superior therapeutic potential, including improved drug release and biocompatibility, suggesting their promise as an effective and safe delivery system for Ranolazine in angina therapy.